Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research

Brown, Powel H.; Viner, Jaye L.; Brewster, Abenaa; Heckman, Carolyn J.; Hursting, Stephen D.; Johnson, Karen; Mao, Jenny T.

doi:10.1158/1940-6207.capr-09-0128

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New strategies for the therapy and prophylaxis of ATL are still required [22]. Antigen‐specific CTL induction is an attractive immunotherapeutic strategy against hematological malignancies, other cancers and infectious diseases [23,24]. Whereas free synthetic antigen peptides have proven to be relatively poor immunogens, antigen‐encapsulating OMLs induce antigen‐specific cell‐mediated immunity that is sufficient to reject tumors or parasites [12,14,25], indicating that OMLs are useful for induction of effective cellular immunity.…”

Section: Discussionmentioning

confidence: 99%

Oligomannose‐coated liposomes efficiently induce human T‐cell leukemia virus‐1‐specific cytotoxic T lymphocytes without adjuvant

Kozako¹,

Hirata²,

Shimizu³

et al. 2011

The FEBS Journal

View full text Add to dashboard Cite

Human T-cell leukemia virus-1 (HTLV-1) causes adult T-cell leukemia ⁄ lymphoma, which is an aggressive peripheral T-cell neoplasm. Insufficient T-cell response to HTLV-1 is a potential risk factor in adult T-cell leukemia ⁄ lymphoma. Efficient induction of antigen-specific cytotoxic T lymphocytes is important for immunological suppression of virusinfected cell proliferation and oncogenesis, but efficient induction of antigen-specific cytotoxic T lymphocytes has evaded strategies utilizing poorly immunogenic free synthetic peptides. Here, we examined the efficient induction of an HTLV-1-specific CD8+ T-cell response by oligomannose-coated liposomes (OMLs) encapsulating the human leukocyte antigen (HLA)-A*0201-restricted HTLV-1 Tax-epitope (OML ⁄ Tax). Immunization of HLA-A*0201 transgenic mice with OML ⁄ Tax induced an HTLV-1-specific gamma-interferon reaction, whereas immunization with epitope peptide alone induced no reaction. Upon exposure of dendritic cells to OML ⁄ Tax, the levels of CD86, major histocompatibility complex class I, HLA-A02 and major histocompatibility complex class II expression were increased. In addition, our results showed that HTLV-1-specific CD8+ T cells can be efficiently induced by OML ⁄ Tax from HTLV-1 carriers compared with epitope peptide alone, and these HTLV-1-specific CD8+ T cells were able to lyse cells presenting the peptide. These results suggest that OML ⁄ Tax is capable of inducing antigen-specific cellular immune responses without adjuvants and may be useful as an effective vaccine carrier for prophylaxis in tumors and infectious diseases by substituting the epitope peptide.Abbreviations ATL, adult T-cell leukemia ⁄ lymphoma; CFSE, 5-(and-6)-carboxy fluorescein diacetate succinimidyl

show abstract

Section: Discussionmentioning

confidence: 99%

Oligomannose‐coated liposomes efficiently induce human T‐cell leukemia virus‐1‐specific cytotoxic T lymphocytes without adjuvant

Kozako¹,

Hirata²,

Shimizu³

et al. 2011

The FEBS Journal

View full text Add to dashboard Cite

show abstract

“…Based on these results, we suggest that with the approach of maximal carboplatin dose and low dose paclitaxel, it may be possible to create an active dose-dense platinum-focussed "scaffold" that can be used to feasibly integrate novel agents that target the reversal of platinum resistance [ 27 ]. With the realisation that delivering carboplatin AUC 3 weekly for 18 cycles is achievable and active in platinum resistant disease, a feasibility study is planned to identify the minimum dose of paclitaxel that is platelet-sparing.…”

Section: Discussionmentioning

confidence: 99%

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

et al. 2011

View full text Add to dashboard Cite

BackgroundPlatinum agents have shown demonstrable activity in the treatment of patients with platinum resistant, recurrent ovarian cancer when delivered in a "dose-dense" fashion. However, the development of thrombocytopenia limits the weekly administration of carboplatin to no greater than AUC 2. Paclitaxel has a well-described platelet sparing effect however its use to explicitly provide thromboprotection in the context of dose dense carboplatin has not been explored.MethodsWe treated seven patients with platinum resistant ovarian cancer who had previously received paclitaxel or who had developed significant peripheral neuropathy precluding the use of further full dose weekly paclitaxel.ResultsWe were able to deliver carboplatin AUC 3 and paclitaxel 20 mg/m2 with no thrombocytopenia or worsening of neuropathic side-effects, and with good activity.ConclusionsWe conclude that this regimen may be feasible and active, and could be formally developed as a "platinum-focussed dose-dense scaffold" into which targeted therapies that reverse platinum resistance can be incorporated, and merits further evaluation.

show abstract

Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women

Bardia

Keenan

Ebbert

et al. 2016

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective To better understand the potential risk/benefit ratio for targeted chemoprevention, we evaluated the association of aspirin and other NSAIDs with incidence of postmenopausal breast cancer for risk subgroups defined by selected non-modifiable or difficult-to-modify breast cancer risk factors. Patients and Methods Postmenopausal women with no history of cancer on July 1, 1992 (N=26,580) were prospectively followed through December 31, 2005 for breast cancer incidence (N=1581). Risk subgroups were defined on family history of breast cancer, age at menarche, age at menopause, parity/age at first live birth, history of benign breast disease, and body mass index (BMI). Hazard ratios (HRs) and 95% confidence intervals (CIs) adjusted for other breast cancer risk factors were estimated using Cox models. Results Aspirin use was associated with a lower incidence of breast cancer for women with family history of breast cancer (HR=0.62 for 6+ per week vs. never use; 95%CI 0.41-0.93) and personal history of benign breast disease (HR=0.69; 95%CI 0.50-0.95), but not for women in higher risk subgroups for age at menarche, age at menopause, parity/age at first live birth or BMI. In contrast, inverse associations with aspirin use were observed in all lower risk subgroups. NSAID use had no association with breast cancer incidence. Conclusion Based on their increased risk of breast cancer, postmenopausal women with a family history of breast cancer or a history of benign breast disease could potentially be targeted for aspirin chemoprevention studies. Future studies are needed to confirm these findings.

show abstract

Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research

Cited by 3 publications

References 0 publications

Oligomannose‐coated liposomes efficiently induce human T‐cell leukemia virus‐1‐specific cytotoxic T lymphocytes without adjuvant

Oligomannose‐coated liposomes efficiently induce human T‐cell leukemia virus‐1‐specific cytotoxic T lymphocytes without adjuvant

Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer

Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women

Contact Info

Product

Resources

About